194 related articles for article (PubMed ID: 25522335)
61. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
Wadhwa VK; Weston R; Mistry R; Parr NJ
BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
[TBL] [Abstract][Full Text] [Related]
62. [Regression of a choroidal metastasis from prostate adenocarcinoma after hormonal therapy].
Barbón JJ; González-Tuero J; Gay LL; Pérez-García FJ; Sampedro A
Arch Soc Esp Oftalmol; 2007 Nov; 82(11):715-7. PubMed ID: 17979041
[TBL] [Abstract][Full Text] [Related]
63. Analysis of the lipid profile and atherogenic risk during androgen deprivation therapy in prostate cancer patients.
Salvador C; Planas J; Agreda F; Placer J; Trilla E; Lopez MA; Morote J
Urol Int; 2013; 90(1):41-4. PubMed ID: 23235105
[TBL] [Abstract][Full Text] [Related]
64. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer.
Koivisto P; Kononen J; Palmberg C; Tammela T; Hyytinen E; Isola J; Trapman J; Cleutjens K; Noordzij A; Visakorpi T; Kallioniemi OP
Cancer Res; 1997 Jan; 57(2):314-9. PubMed ID: 9000575
[TBL] [Abstract][Full Text] [Related]
65. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
66. Etoricoxib and intermittent androgen deprivation therapy in patients with biochemical progression after radical prostatectomy.
Di Silverio F; Sciarra A; Gentile V
Urology; 2008 May; 71(5):947-51. PubMed ID: 18279940
[TBL] [Abstract][Full Text] [Related]
67. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer.
Palmberg C; Koivisto P; Kakkola L; Tammela TL; Kallioniemi OP; Visakorpi T
J Urol; 2000 Dec; 164(6):1992-5. PubMed ID: 11061898
[TBL] [Abstract][Full Text] [Related]
68. [Antiandrogen in prostate cancer].
Maeda O; Usami M
Nihon Rinsho; 2002 Dec; 60 Suppl 11():188-92. PubMed ID: 12599569
[No Abstract] [Full Text] [Related]
69. Prognostic markers in salivary gland cancer and their impact on survival.
Szewczyk M; Marszałek A; Sygut J; Golusiński P; Golusiński W
Head Neck; 2019 Sep; 41(9):3338-3347. PubMed ID: 31246357
[TBL] [Abstract][Full Text] [Related]
70. Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404).
Ho AL; Foster NR; Zoroufy AJ; Campbell JD; Worden F; Price K; Adkins D; Bowles DW; Kang H; Burtness B; Sherman E; Morton R; Morris LGT; Nadeem Z; Katabi N; Munster P; Schwartz GK
J Clin Oncol; 2022 Dec; 40(36):4240-4249. PubMed ID: 35867947
[TBL] [Abstract][Full Text] [Related]
71. First Line Androgen Deprivation Therapy vs. Chemotherapy for Patients With Androgen Receptor Positive Recurrent or Metastatic Salivary Gland Carcinoma-A Retrospective Study.
Viscuse PV; Price KA; Garcia JJ; Schembri-Wismayer DJ; Chintakuntlawar AV
Front Oncol; 2019; 9():701. PubMed ID: 31428578
[No Abstract] [Full Text] [Related]
72. Androgen Deprivation Therapy for Patients with Androgen-Receptor-Positive Metastatic Salivary Duct Carcinoma: A Case Report and Review of the Literature.
You Y; Wang P; Wan X; Xu L; Gong Y; Zhang W
Onco Targets Ther; 2021; 14():3481-3486. PubMed ID: 34093024
[TBL] [Abstract][Full Text] [Related]
73. Systemic therapy in metastatic salivary gland carcinomas: A pathology-driven paradigm?
Alfieri S; Granata R; Bergamini C; Resteghini C; Bossi P; Licitra LF; Locati LD
Oral Oncol; 2017 Mar; 66():58-63. PubMed ID: 28249649
[TBL] [Abstract][Full Text] [Related]
74. An Androgen Receptor-positive Carcinoma of the Lacrimal Drainage System Resembling Salivary Duct Carcinoma: Case Report and Review of the Literature.
Rahimi S; Lambiase A; Brennan PA; Abdolrahimzadeh S
Appl Immunohistochem Mol Morphol; 2016 Sep; 24(8):e69-71. PubMed ID: 26766124
[TBL] [Abstract][Full Text] [Related]
75. Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer.
Hanna GJ; Guenette JP; Chau NG; Sayehli CM; Wilhelm C; Metcalf R; Wong DJ; Brose M; Razaq M; Pérez-Ruiz E; Cohen EEW; Aggarwal R; Scholz C; Gualberto A; Ho AL
Cancer; 2020 Sep; 126(17):3972-3981. PubMed ID: 32557577
[TBL] [Abstract][Full Text] [Related]
76. Capecitabine is effective as palliative chemotherapy in a patient with androgen receptor and HER2 positive metastatic salivary duct carcinoma. A case report.
Čavka L; Zakotnik B
J Cancer Res Ther; 2023 Oct; 19(7):2048-2051. PubMed ID: 38376316
[TBL] [Abstract][Full Text] [Related]
77. Acquisition of resistance to androgen deprivation therapy in salivary duct carcinoma: A case report.
Wasano K; Sakurai K; Kawasaki T; Kusafuka K; Kasahara M; Kondo N; Inada KI; Ogawa K
Rare Tumors; 2018; 10():2036361318798867. PubMed ID: 30263102
[TBL] [Abstract][Full Text] [Related]
78. Androgen Receptor Signaling in Salivary Gland Cancer.
Dalin MG; Watson PA; Ho AL; Morris LG
Cancers (Basel); 2017 Feb; 9(2):. PubMed ID: 28208703
[TBL] [Abstract][Full Text] [Related]
79. Advanced salivary gland carcinoma expressing androgen receptor and HER2: targeted therapies first?
Quaquarini E; Sottotetti F; Presti D
Ann Oncol; 2020 Jul; 31(7):958-959. PubMed ID: 32275947
[No Abstract] [Full Text] [Related]
80. Androgen Receptor Pathway in Salivary Gland Cancer.
Ho AL
J Clin Oncol; 2021 Dec; 39(36):4069-4072. PubMed ID: 34597118
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
